Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Xenetic Biosciences, Inc. (XBIOW)

    Price:

    17.54 USD

    ( - -5.40 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    XBIOW
    Name
    Xenetic Biosciences, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    17.540
    Market Cap
    5.625M
    Enterprise value
    -15.625k
    Currency
    USD
    Ceo
    James F. Parslow
    Full Time Employees
    4
    Ipo Date
    2019-07-23
    City
    Framingham
    Address
    945 Concord Street

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    BioNTech SE

    VALUE SCORE:

    6

    Symbol
    BNTX
    Market Cap
    22.384B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Atara Biotherapeutics, Inc.

    VALUE SCORE:

    11

    Symbol
    ATRA
    Market Cap
    36.484M
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Harmony Biosciences Holdings, Inc.

    VALUE SCORE:

    11

    Symbol
    HRMY
    Market Cap
    1.624B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -1.148
    P/S
    1.268
    P/B
    0.916
    Debt/Equity
    0
    EV/FCF
    0.183
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    -0.174
    Earnings yield
    -0.871
    Debt/assets
    0
    FUNDAMENTALS
    Net debt/ebidta
    1.253
    Interest coverage
    0
    Research And Developement To Revenue
    1.166
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.000
    Capex to revenue
    0.000
    Capex to depreciation
    0
    Return on tangible assets
    -0.623
    Debt to market cap
    0
    Piotroski Score
    3.000
    FUNDAMENTALS
    PEG
    0.477
    P/CF
    -1.384
    P/FCF
    -1.384
    RoA %
    -62.280
    RoIC %
    -83.684
    Gross Profit Margin %
    100.000
    Quick Ratio
    4.558
    Current Ratio
    4.558
    Net Profit Margin %
    -110.401
    Net-Net
    1.952
    FUNDAMENTALS PER SHARE
    FCF per share
    -1.762
    Revenue per share
    1.854
    Net income per share
    -2.047
    Operating cash flow per share
    -1.762
    Free cash flow per share
    -1.762
    Cash per share
    2.673
    Book value per share
    2.565
    Tangible book value per share
    2.565
    Shareholders equity per share
    2.565
    Interest debt per share
    0
    TECHNICAL
    52 weeks high
    20.500
    52 weeks low
    1.020
    Current trading session High
    17.540
    Current trading session Low
    16.700
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    CA
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.308
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -20.642

    No data to display

    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -1.6242092%
    P/E
    -0.301
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.971

    No data to display

    logo

    Country
    IE
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Pharmaceuticals
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.053
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.104
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.028

    No data to display

    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -6.426
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.084
    DESCRIPTION

    Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

    NEWS